In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.
A new study by Precision co-authors Andrew Delgado and Jinjoo Shim, along with scientific advisors John Romley and Katherine Batt, assesses the value to society of improved survival from novel immune-oncology treatments. With the data compiled, the study team concluded that there is evidence of substantial survival gains, and thus, social value.
In a featured article for PM360, Precision’s Ross Maclean and Phil Cyr identify three themes and eight interrelated factors which, if overlooked, can negatively impact a launch. In short, prescribers remain Very Important People in a launch, facing challenges around Vulnerability, Incentives, and Personalization.
Randomized controlled trials don’t capture real-world evidence regarding how patients will actually interact with, adhere to, or find value in a costly new medical therapy, yet current value frameworks and assessments don’t include this “real world” element. A new working group led by PHE’s Anupam Jena, Jacki Chou, and Darius Lakdawalla aim to improve this dynamic by offering guidance on closing the gap between real-world and clinical trial data when formulating value frameworks.
PHE recently published a new study in collaboration with Genalyte on the potential value of rapid, cloud-enabled, onsite laboratory testing for the diagnosis of rheumatoid arthritis. The study found that this technology could generate value of over $5,000 per evaluated patient-year. The study was led by PHE’s Kata Bognar, Jason Shafrin, Michelle Brauer, Lauren Zhao, and Bapu Jena. […]
For more information, or to learn how to change your cookies preferences, please click here.